Tesla (NASDAQ:TSLA): RW Baird downgraded Tesla to Neutral from Outperform based on valuation and would be more constructive on execution-related share weakness or significant advances in battery technology. The shares’ price target remains $187.
Baxter (NYSE:BAX): Credit Suisse downgraded Baxter to Neutral from Outperform following a U.S. long-acting recombinant FVIII’s adoption survey that was disappointing and which indicated meaningful downside to estimates. The firm believes shares will remain range-bound until the second half of 2014, and the shares’ price target has been lowered to $73 from $81.
Broadcom (NASDAQ:BRCM): Benchmark Co. lowered its price target for Broadcom to $35 from $40, citing near-term dilution from the Renesas assets acquisition, but the firm keeps a Buy rating on the stock.
Biogen (NASDAQ:BIIB): Credit Suisse raised Biogen estimates and its price target to $290 from $255 based on higher Tecfidera and Hemophilia sales estimates. The shares are Outperform rated.
Don’t Miss: 7 Entry-Level Luxury Rides to Work Toward.